Inflammation within areas of interstitial fibrosis and tubular atrophy (i-IFTA) is associated with adverse outcomes in kidney transplantation. We evaluated i-IFTA in 429 indicationand 2052 protocol-driven biopsy samples from a longitudinal cohort of 362 kidneypancreas recipients to determine its prevalence, time course, and relationships with T cell-mediated rejection (TCMR), immunosuppression, and outcome. Sequential histology demonstrated that i-IFTA was preceded by cellular interstitial inflammation and followed by IF/TA. The prevalence and intensity of i-IFTA increased with developing chronic fibrosis and correlated with inflammation, tubulitis, and immunosuppression era (P < .001).
| INTRODUCTION
T cell-mediated rejection (TCMR) is characterized by interstitial lymphocytic infiltration and tubulitis of the allograft, semiquantitatively coded by i and t Banff scores, respectively, and formulated into diagnostic categories for acute TCMR.
1 Originally optimized for early acute rejection appearing within unscarred kidneys by the Banff consensus in 1991, it still underpins the current diagnostic schema of TCMR. but is applied only to scarred cortical parenchyma. Its impact has been sporadically reported: by us from 2004 and designated as "cdi" score using current definitional thresholds 6 ; by Sellares (2007, 2009 , and 2011, designated as "i-IFTA" and also quantified by the absolute proportion of total cortex affected) [7] [8] [9] ; and by Mannon and DEKAF investigators (in 2010, designated "iatr" as "inflammation in areas of tubular atrophy," using the current definition). 4 i-IFTA in indication biopsies strongly predicted death-censored graft failure (independent of renal function, IF/TA, and inflammation scores) in the DEKAF study, 4 confirming findings from Edmonton. 7 The i-IFTA pattern is not synonymous with the total inflammation (ti) score (counting total cortical inflammation) 1, 9 or the Boolean combination of Banff i inflammation occurring with IF/TA ("i+IF/TA"), although both demonstrate adverse outcomes, including renal dysfunction, 10,11 nephron attrition by serial pathology, [11] [12] [13] de novo donor-specific antibodies (DSAs), 12, 14 and allograft failure. 13, 15, 16 The mechanisms and causal relationships between i-IFTA and TCMR, their biological, functional, and histologic outcomes, require further investigation.
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We hypothesized that (1) 
| METHODS AND MATERIALS

| Study population and immunosuppression
The study group consisted of kidney-pancreas recipients transplanted from 1987 to 2012, for whom a minimum of 1-year histologic follow-up was available. Implanted kidneys were pristine and unscarred at transplantation. Recipients underwent regular, prospective protocol kidney transplant biopsies from implantation until 10 years after transplantation, with additional indication biopsies as clinically indicated. 18 Triple therapy immunosuppression consisted of cyclosporine until its replacement by tacrolimus in 1999
(target levels adjusted clinical events, rejection, nephrotoxicity, and side effects), azathioprine replaced by mycophenolate mofetil in 1996, and prednisolone throughout. Induction by antilymphocyte preparations was reserved for highly sensitized recipients. Patients received optimal kidneys from younger deceased donors, eliminating recurrent disease and donor quality as confounding factors, and leaving alloimmune mechanisms as the dominant driver of injury in this cohort.
| Histologic assessment of i-IFTA
Needle-core protocol biopsy samples were taken at implantation and 1 week (early era only); at 1, 3, 6, and 12 months; and then annually or second/third yearly for 10 years, as described. 19 Specialist nephropathologists scored for individual parameters and classified by rejection phenotypes using the Banff schema. i-IFTA2 = 26% to 50%; and i-IFTA3 = greater than 50% of scarred cortical parenchyma, as originally described and used consistently to date.
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| Specific study aims
The specific study aims were to: 
| Data analysis
The research design was a single-center, observational cohort study, with retrospective analysis of prospectively collected protocol pathol- All tests were 2-tailed, and a probability < .05 was considered significant. Figure S1 ). These included 33 (3. 
| RESULTS
| Demographic and study group data
| Time course of i-IFTA by sequential histology
The the presence of i-IFTA was predicted by coexistent interstitial infiltrate (P = .002), fibrosis (P < .001), and glomerulopathy scores (P = .047; Table 2 ). The percentage of scarred cortex with active inflammation was 38.7% at 3 months and 70.8% for late biopsies (≥3 months, n = 430 beyond the early acute rejection period); with 61.5% to 68.9% for 5 to 10 years posttransplantation (n = 370 biopsies, mean = 77.8% overall).
| One-year i-IFTA and antecedent events
One-year protocol histology found i-IFTA in 31.9% (91/285 available; Table 3 , full data given in Table S5 ), which correlated with prior events, immunosuppression era, and subsequent histology. Using logistic regression, 1-year i-IFTA was predicted by all prior rejection phenotypes; requirement of antilymphocyte therapy to reverse severe rejection; markers of sensitization including prior transfusions, PRA, and DSA; and nonimmune factors such as anastomosis time (Table 4) . Only early T cell rejection and peak PRA remained significant by multivariable regression (Table 4) . Most early humoral rejection episodes were of mixed phenotype, with accompanying interstitial inflammation (data not presented). Cox regression of all 2361 sequential posttransplantation kidney biopsy samples (to detect the new onset of a histologic change from the time of transplantation) identified the same immune (and some nonimmune/ischemic) risk factors for development of i-IFTA (Table 5 , full data given in Table S6 Table S7 ). Additional sensitivity analyses of the forced addition of antibody-mediated rejection into the multivariable Cox regression model demonstrated no effect on i-IFTA development (Table S7 ).
| Effect of immunosuppression era on i-IFTA
The incidence, point-prevalence, and intensity of i-IFTA were evalu- Tables 3, 4, 5, S5, S6, and S7). Tacrolimus-era therapy was associated with altered cellular kinetics into the i-IFTA compartment involving: (i) reduced intensity and duration of early inflammation within the interstitial compartment,
(ii) lower de novo i-IFTA formation, prevalence, and intensity of inflammation, and (iii) increased conversion rates of active i-IFTA to inactive IF/TA (all P < .001; Figure 4 , methodology detailed in Table S1 ) compared with cyclosporine. By Cox regression, tacrolimus increased conversion of active to inactive fibrosis (median 1 year, 95% CI 1-1.5 years) compared with cyclosporine (6 years, 95% CI 3-9 years, P < .001).
| Histologic and functional associations with i-IFTA
The histologic associations of i-IFTA from 1-year pathology were (P < .001; Figure 5 ), excess fibrointimal hyperplasia, and a mild increase in chronic transplant glomerulopathy (coded Banff cg, all cases confirmed by electron microscopy; Figure 5 ). Abnormalities began soon after transplantation and continued for the study duration. adjusted for acute tubular necrosis and interstitial edema (both P < .05; Table 6 ). In kidneys developing i-IFTA at 1 year, early serum creatinine concentrations were elevated from hospital discharge (P < .05 to .001 to 3 months), remaining abnormal from 3-month protocol isotopic mGFR (P < .001) until 10 years ( Figure 6 ).
The 10-year death-censored graft survival for 1-year i-IFTA was 87.6% (versus 93.0% for no i-IFTA, log-rank 0.100, P = .752); however, i-IFTA modestly increased late graft loss with longer follow-up (log-rank 3.027, P = .082; Figure 7 ). The overall 10-year graft survival (including death with function) was 71.6% (and unrelated to i-IFTA, log-rank 1.351, P = .245). One-year i-IFTA had no effect on patient mortality (median survival 21.25 and 21.92 years, respectively, logrank 0.100, P = .752; Figure 7 ). Deaths (53/362) were primarily from cardiovascular causes (35/52, 67.3%).
| DISCUSSION
This large, longitudinal cohort study illustrates i-IFTA is an important time-dependent histologic lesion: denoting the interface between T 
Occurrence of i-IFTA Odds ratio 95% CI P value
Interstitial infiltrate (i score) DSA, donor-specific antibody; MFI, median fluorescence intensity; OR, odds ratio; CI, confidence interval.
T For full data, event rates, and numbers see Table S6 ; for additional models, see Table S7 . DSA, donor-specific antibody; MFI, median fluorescence intensity.
calcineurin inhibitor. Alterations of kinetics by immunosuppression era suggest i-IFTA intensity scores reflect the summated effects of cellular influx, available IF/TA area, and (a variable) resolution phase where i-IFTA could transition to inactive fibrosis (although potential reactivation from underimmunosuppression could still recur; Figure 4 ).
To evaluate whether i-IFTA was initiated and driven by T cellmediated alloimmunity, we applied published epistemological criteria 27 to these data to test the causal hypothesis (detailed in Table S8 ). The temporal sequence consisted of initial cellular inflammation followed TCMR) all suggest a cellular alloimmunity was responsible for i-IFTA, rather than nonspecific response to injury. The colocalization of interstitial inflammation with i-IFTA also supports a specific mechanistic effect and is implicit by definition. 3 Other studies using alternative experimental designs (eg, cross-sectional indication pathology) reached the same conclusions. [4] [5] [6] [7] [8] The hypothesis that T cell-mediated injury causes i-IFTA is biologically plausible, logically coherent, and consistent with known relationships of subclinical inflammation and IF/TA 14, 28, 29 and constitutes the best explanation of observed pathology. with the TAC era (left, middle, and right middle panels, respectively). The kinetics of inflammatory fibrosis, encompassing the onset and resolution of i-IFTA according to immunosuppression era, are illustrated in the bottom panels using actuarial methodology. CSA era was associated with greater de novo development of i-IFTA (left bottom), whereas TAC era produced a greater likelihood of resolution of active i-IFTA to inactive IF/TA (i-IFTA0 state), illustrated by Kaplan-Meier conversion rates (bottom middle) and the "instantaneous hazard" (as the conversion to inactive fibrosis, bottom right panel). Overall, TAC-era therapy was associated with a comprehensive reduction in the intensity of early inflammation, i-IFTA and IF/TA development, ongoing mean i-IFTA intensity scores, and enhanced abatement to inactive i-IFTA states, compared with CSA era (numbers at risk, see Figure S2 ). Values given as mean ± SEM. ***P < .001 ) and modestly affected transplant glomerulopathy (confirmed by electron microscopy as chronic humoral rejection).
One-year i-IFTA correlated with early renal dysfunction (from early alloimmune injury and predating histology) and impaired GFR extending over the allograft's lifetime ( Figure 6 ). The numerically inferior allograft survival following 1-year protocol i-IFTA from these young deceaseddonor kidneys echoed findings of late indication biopsy studies with allograft dysfunction. 4, 5, 7, 31 The multicenter DEKAF study of 337 indication biopsies found i-IFTA strongly predicted death-censored graft failure compared with no inflammation, independent of renal Comparison by immunosuppression era allows differentiation between immune i-IFTA from reactive inflammation, although historically controlled data require cautious interpretation because of potential residual confounding bias (including the presence of pretransplantation DSAs and unrecognized era effects). However, patient and implanted kidney demographics were exceptionally constant between eras, and F I G U R E 7 Death-censored allograft survival was only modestly worse in kidneys with 1-year interstitial inflammation within areas of interstitial fibrosis and tubular atrophy (i-IFTA) on protocol histology, occurring relatively late posttransplantation (left panel, P = .082) and without any effect on recipient survival (middle panel, numbers at risk, see Figure S2 ). Right panel, the prevalence of i-IFTA according to clinical scenario (see discussion for comparative data from other studies). Stack bar illustrates i-IFTA categories from protocol biopsy samples (no rejection or subclinical rejection [SCR]), and indication biopsy by acute T cell rejection phenotype (BL borderline, Banff IA or IB interstitial rejection, and Banff type II vascular rejection) for comparisons with other studies (see discussion)
our longitudinal protocol biopsy regimen has continued. The 2 eras were easily distinguishable by their overall level of alloimmune activity, including acute and subclinical rejection rates. Because this study includes older historical patients, the overall rejection rates (and i-IFTA incidence) were greater than those of the current era. Our study was a nonrandomized, observational, single-center cohort design. Although analyses were retrospectively undertaken, histologic and clinical data were prospectively collected as per protocol and scored according to the standardized Banff schema. This study presents the largest histologic evaluation of i-IFTA with comprehensive clinical data to date.
In summary, these data support the concept that i-IFTA is mediated by chronic active T cellular processes and is associated with progressive tubular atrophy and secondary interstitial fibrosis, renal dysfunction, and histologic deterioration. i-IFTA appears susceptible to an environment of effective immunosuppression and, when persistent, represents a pathologic expression of chronic TCMR, albeit as a nonspecific phenotype of active tubular destruction.
